N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer

Intrinsic and acquired anti-HER2 resistance remains a major hurdle for treating HER2-positive breast cancer. Using genome-wide CRISPR/Cas9 screening in vitro and in vivo, we identify FGFR4 as an essential gene following anti-HER2 treatment. FGFR4 inhibition enhances susceptibility to anti-HER2 thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Yutian, Zheng, Shaoquan, Xie, Xinhua, Ye, Feng, Hu, Xiaoqian, Tian, Zhi, Yan, Shu-Mei, Yang, Lu, Kong, Yanan, Tang, Yuhui, Tian, Wenwen, Xie, Jindong, Deng, Xinpei, Zeng, Yan, Chen, Zhe-Sheng, Tang, Hailin, Xie, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106694/
https://www.ncbi.nlm.nih.gov/pubmed/35562334
http://dx.doi.org/10.1038/s41467-022-30217-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106694/
https://www.ncbi.nlm.nih.gov/pubmed/35562334
http://dx.doi.org/10.1038/s41467-022-30217-7

Ejemplares similares